Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
The NLR-2c value is useful for predicting PFS in u-HCC patients treated with Dur/Tre therapy.
Authors
- Atsushi Ozasa
- Satoshi Narahara (ORCID: https://orcid.org/0000-0001-8647-9486)
- Yoshihide Kimura (ORCID: https://orcid.org/0000-0003-4801-8384)
- Yasuhito Tanaka (ORCID: https://orcid.org/0000-0002-2473-6966)
- Shunsuke Nojiri
- Hiroki Inada (ORCID: https://orcid.org/0000-0002-3456-6921)
- Hiromu Kondo (ORCID: https://orcid.org/0000-0002-1277-6821)
- Kaiki Anbe
- Hiromi Kataoka (ORCID: https://orcid.org/0000-0001-9491-0723)
- Takayuki Tokunaga (ORCID: https://orcid.org/0000-0002-3631-4525)
- Kohei Okayama
- Hayato Kawamura (ORCID: https://orcid.org/0000-0002-7679-4279)
- Tsutomu Mizoshita (ORCID: https://orcid.org/0000-0003-0460-5288)
- Kentaro Matsuura (ORCID: https://orcid.org/0009-0005-0163-3971)
- Takanori Suzuki (ORCID: https://orcid.org/0000-0002-8940-2393)
- Fumihiro Okumura
- K. Hayashi (ORCID: https://orcid.org/0000-0002-8262-3425)
- Kei Fujiwara (ORCID: https://orcid.org/0000-0002-2278-2088)
- Daisuke Kato
- Satoshi Sobue
Institutions
- Nagoya City University (JP)
- Gifu Prefectural Tajimi Hospital (JP)
- Toyokawa City Hospital (JP)
- Kasugai Municipal Hospital (JP)
- Nagasaki Rousai Hospital (JP)
- Nagoya Medical Center (JP)
- Japanese Red Cross Nagoya Daini Hospital (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1111/hepr.14189
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29
Funders
- Japan Society for the Promotion of Science